We are live on ! Find out more
CELZ icon

Creative Medical Technology

13 hedge funds and large institutions have $552K invested in Creative Medical Technology in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

510% more capital invested

Capital invested by funds: $90.4K → $552K (+$461K)

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

63% more funds holding

Funds holding: 813 (+5)

6.38% more ownership

Funds ownership: 1.42%7.8% (+6.4%)

Holders
13
Holders Change
+5
Holders Change %
+62.5%
% of All Funds
0.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
3
Reduced
Closed
2
Calls
Puts
Net Calls
Net Calls Change

CELZ Hedge Fund Activity: Q1 2024 in Review

13 of the 6,957 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q1 2024, worth a combined $552K — up 510% from $90.4K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CELZ positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Aaron Wealth Advisors, opening a new position worth an estimated $76.3K. The largest seller was IFP Advisors, exiting entirely with an estimated $23 sold.

  • 13 institutional investors held Creative Medical Technology (CELZ) as of Q1 2024, up from 8 in Q4 2023.
  • Funds reported $552K of Creative Medical Technology stock for Q1 2024, up 510% quarter-over-quarter.
  • 7 funds opened new Creative Medical Technology positions in Q1 2024 and 2 closed out, a net change of +5 holders.
  • The largest Creative Medical Technology buyer in Q1 2024 was Aaron Wealth Advisors, an estimated $76.3K added.
  • The largest Creative Medical Technology seller in Q1 2024 was IFP Advisors, an estimated $23 sold.

Based on aggregated 13F filings for Q1 2024.